In the PDX models, which also showed varying BCL-2 family protein levels, while DR_MOMP predicted a differential response to ABT-199 and FOLFOX for CRC0076 and CRC0344, an n-fold greater BCL-2 concentration in one tumour did not translate to an n-fold higher requirement for BCL-2 antagonists (Figure 2A,B). The gene discussed is BCL2; the disease is neoplasm.